-
2
-
-
80155204725
-
Assessment of lupus nephritis cohort over a 30-year period
-
Croca S, Rodrigues T, Isenberg DA. Assessment of lupus nephritis cohort over a 30-year period. Rheumatology 2011;50:1424-30.
-
(2011)
Rheumatology
, vol.50
, pp. 1424-1430
-
-
Croca, S.1
Rodrigues, T.2
Isenberg, D.A.3
-
3
-
-
84945222214
-
B cells in systemic lupus erythematosus
-
Wallace DJ, Hahn BH. eds, 7th edn. Philadelphia, PA: Lippincott, Williams & Wilkins
-
Stamatis-Nick C, Tsokos GC. B cells in systemic lupus erythematosus. In: Wallace DJ, Hahn BH. eds. Dubois Lupus Erythematosus. 7th edn. Philadelphia, PA: Lippincott, Williams & Wilkins, 2007:176-90.
-
(2007)
Dubois Lupus Erythematosus
, pp. 176-190
-
-
Stamatis-Nick, C.1
Tsokos, G.C.2
-
4
-
-
84871838942
-
B cell elimination in systemic lupus erythematosus
-
Furtado J, Isenberg DA. B cell elimination in systemic lupus erythematosus. Clin Immunol 2013;146:90-103.
-
(2013)
Clin Immunol
, vol.146
, pp. 90-103
-
-
Furtado, J.1
Isenberg, D.A.2
-
5
-
-
74849131972
-
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial
-
Merrill JT, Neuelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33.
-
(2010)
Arthritis Rheum
, vol.62
, pp. 222-233
-
-
Merrill, J.T.1
Neuelt, C.M.2
Wallace, D.J.3
-
6
-
-
84866184129
-
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study
-
Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215-26.
-
(2012)
Arthritis Rheum
, vol.64
, pp. 1215-1226
-
-
Rovin, B.H.1
Furie, R.2
Latinis, K.3
-
7
-
-
79952070370
-
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomized placebo-controlled, phase 3 trial
-
Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomized placebo-controlled, phase 3 trial. Lancet 2011;377:721-31.
-
(2011)
Lancet
, vol.377
, pp. 721-731
-
-
Navarra, S.V.1
Guzmán, R.M.2
Gallacher, A.E.3
-
8
-
-
82455198794
-
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
-
Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30.
-
(2011)
Arthritis Rheum
, vol.63
, pp. 3918-3930
-
-
Furie, R.1
Petri, M.2
Zamani, O.3
-
9
-
-
37149032474
-
Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicentre, phase 1b, double-blind, placebo-controlled, dose-escalating trial
-
Dall'Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicentre, phase 1b, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007;56:4142-50.
-
(2007)
Arthritis Rheum
, vol.56
, pp. 4142-4150
-
-
Dall'Era, M.1
Chakravarty, E.2
Wallace, D.3
-
10
-
-
0037108490
-
BLyS and April form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases
-
Roschke V, Sosnovtseva S, Ward CD, et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002;169:4314-21.
-
(2002)
J Immunol
, vol.169
, pp. 4314-4321
-
-
Roschke, V.1
Sosnovtseva, S.2
Ward, C.D.3
-
11
-
-
0347285357
-
BCMA is essential for the survival of long-lived bone marrow plasma cells
-
O'Connor BP, Raman VS, Erickson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004;199:91-8.
-
(2004)
J Exp Med
, vol.199
, pp. 91-98
-
-
O'Connor, B.P.1
Raman, V.S.2
Erickson, L.D.3
-
12
-
-
0027325557
-
The BILAG index: A reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus
-
Hay EM, Bacon P, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. QJ Med 1993;86:447-58.
-
(1993)
QJ Med
, vol.86
, pp. 447-458
-
-
Hay, E.M.1
Bacon, P.2
Gordon, C.3
-
13
-
-
17744370325
-
From BILAG to BLiPS-disease activity assessment in lupus past, present and future
-
Isenberg DA, Gordon C; on behalf of the BILAG group. From BILAG to BLiPS-disease activity assessment in lupus past, present and future. Lupus 2000;9:651-4.
-
(2000)
Lupus
, vol.9
, pp. 651-654
-
-
Isenberg, D.A.1
Gordon, C.2
-
14
-
-
0020436689
-
The 1982 revised criteria for the classification of systemic lupus erythematosus
-
Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-2.
-
(1982)
Arthritis Rheum
, vol.25
, pp. 1271-1272
-
-
Tan, E.M.1
Cohen, A.S.2
Fries, J.F.3
-
15
-
-
0031229830
-
Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus (letter)
-
Hochberg MC. Updating the American College of Rheumatology Revised Criteria for the Classification of Systemic Lupus Erythematosus (letter). Arthritis Rheum 1997;40:1725.
-
(1997)
Arthritis Rheum
, vol.40
, pp. 1725
-
-
Hochberg, M.C.1
-
16
-
-
34447320202
-
Fifty years of anti-dsDNA antibodies-are we approaching journey's end?
-
Isenberg DA, Manson JJ, Ehrenstein MR, et al. Fifty years of anti-dsDNA antibodies-are we approaching journey's end? Rheumatology 2007;46:1052-6.
-
(2007)
Rheumatology
, vol.46
, pp. 1052-1056
-
-
Isenberg, D.A.1
Manson, J.J.2
Ehrenstein, M.R.3
-
18
-
-
84856795563
-
Atacicept in combination with MMF and corticosteroids in lupus nephritis: Results of a prematurely terminated trial
-
Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 2012;14:R33.
-
(2012)
Arthritis Res Ther
, vol.14
, pp. R33
-
-
Ginzler, E.M.1
Wax, S.2
Rajeswaran, A.3
-
19
-
-
79959856423
-
Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase II, randomized, placebo-controlled trial
-
Van Vollenhoven RF, Kinnman N, Vincent E, et al. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum 2011;63:1782-92.
-
(2011)
Arthritis Rheum
, vol.63
, pp. 1782-1792
-
-
Van Vollenhoven, R.F.1
Kinnman, N.2
Vincent, E.3
-
20
-
-
74849131972
-
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial
-
Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33.
-
(2010)
Arthritis Rheum
, vol.62
, pp. 222-233
-
-
Merrill, J.T.1
Neuwelt, C.M.2
Wallace, D.J.3
-
21
-
-
0242524630
-
Definition and treatment of lupus flare measured by the BILAG index
-
Gordon C, Sutcliffe N, Skan J, et al. Definition and treatment of lupus flare measured by the BILAG index. Rheumatology 2003;42:1372-9.
-
(2003)
Rheumatology
, vol.42
, pp. 1372-1379
-
-
Gordon, C.1
Sutcliffe, N.2
Skan, J.3
|